Related Experiment Videos
Unoprostone (isopropyl unoprostone)
1Adis International Limited, Auckland, New Zealand.
Drugs & Aging
|September 1, 1996
Summary
Unoprostone effectively lowers intraocular pressure (IOP) by enhancing aqueous humor outflow, showing comparable efficacy to timolol in glaucoma patients. Adverse events were primarily local, with fewer systemic effects observed.
Area of Science:
- Ophthalmology
- Pharmacology
- Ocular Therapeutics
Background:
- Unoprostone is a docosanoid related to prostaglandin F2 alpha metabolites.
- It exhibits oculo-hypotensive effects, reducing intraocular pressure (IOP).
Purpose of the Study:
- To evaluate the efficacy and safety of unoprostone in lowering IOP.
- To compare unoprostone's efficacy with timolol in glaucoma patients.
Main Methods:
- Clinical studies (Phase II and III) involving healthy volunteers and patients with glaucoma or ocular hypertension.
- Instillation of unoprostone 0.12% and comparison with timolol 0.5%.
Main Results:
- Unoprostone 0.12% significantly reduced IOP in healthy volunteers and patients.
- Efficacy was comparable to timolol 0.5% in primary open-angle glaucoma and ocular hypertension.
- Adverse events were mainly local, with infrequent systemic effects.
Conclusions:
- Unoprostone is an effective agent for lowering intraocular pressure.
- It offers a favorable safety profile, with predominantly local side effects.
- Unoprostone presents a viable therapeutic option for managing glaucoma and ocular hypertension.